Amphastar Pharmaceuticals, Inc. $AMPH Shares Bought by TD Asset Management Inc

TD Asset Management Inc raised its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.6% during the fourth quarter, Holdings Channel reports. The firm owned 1,963,052 shares of the company’s stock after purchasing an additional 31,160 shares during the period. TD Asset Management Inc’s holdings in Amphastar Pharmaceuticals were worth $52,571,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Amphastar Pharmaceuticals by 24.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock valued at $60,000 after acquiring an additional 435 shares during the period. Farther Finance Advisors LLC raised its stake in shares of Amphastar Pharmaceuticals by 46.3% in the 4th quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock valued at $37,000 after acquiring an additional 437 shares during the period. ProShare Advisors LLC raised its stake in shares of Amphastar Pharmaceuticals by 5.3% in the 4th quarter. ProShare Advisors LLC now owns 9,083 shares of the company’s stock valued at $243,000 after acquiring an additional 457 shares during the period. GAMMA Investing LLC raised its stake in shares of Amphastar Pharmaceuticals by 37.8% in the 4th quarter. GAMMA Investing LLC now owns 1,685 shares of the company’s stock valued at $45,000 after acquiring an additional 462 shares during the period. Finally, Advisory Research Inc. raised its stake in shares of Amphastar Pharmaceuticals by 3.8% in the 3rd quarter. Advisory Research Inc. now owns 15,468 shares of the company’s stock valued at $412,000 after acquiring an additional 570 shares during the period. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock opened at $19.74 on Friday. Amphastar Pharmaceuticals, Inc. has a 12 month low of $16.65 and a 12 month high of $31.26. The company has a debt-to-equity ratio of 0.79, a current ratio of 3.85 and a quick ratio of 2.82. The firm has a market capitalization of $870.34 million, a P/E ratio of 11.89, a P/E/G ratio of 3.68 and a beta of 0.91. The company’s fifty day moving average price is $20.03 and its two-hundred day moving average price is $23.58.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). Amphastar Pharmaceuticals had a return on equity of 15.12% and a net margin of 11.00%.The firm had revenue of $171.17 million during the quarter, compared to analyst estimates of $173.46 million. On average, research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 2.41 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on AMPH. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Friday, May 8th. Jefferies Financial Group reissued a “hold” rating and issued a $22.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, April 21st. Wells Fargo & Company reissued an “equal weight” rating and issued a $19.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Thursday, May 14th. Piper Sandler reissued a “neutral” rating and issued a $21.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 11th. Finally, Weiss Ratings downgraded shares of Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, April 10th. Seven investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $24.00.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.